I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
John Joseph Laterra, M.D., Ph.D.
Co-Director, Brain Cancer Program, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Professor of Neurology
Expertise: Brain Tumors, Neurology, Von Hippel-Lindau (VHL)
Research Interests: Mechanisms of Brain Cancer Stem Cell Regulation
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
As Professor of Neurology, Oncology and Neuroscience and co-Director of the Brain Cancer Program at the Johns Hopkins Kimmel Cancer Center, Dr. John Laterra focuses on the diagnosis and treatment of patients with primary brain tumors and neurological complications of systemic cancer.
Dr. Laterra is internationally recognized for his clinical expertise and research on mechanisms of brain tumor malignancy, tumor vascular biology and the identification of new therapeutic targets in gliomas. Dr. Laterra's research is funded by the National Institutes of Health and numerous private foundations.
- Co-Director, Brain Cancer Program, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
- Director, Division of Neuro-Oncology
- Professor of Neurology
- Professor of Neuroscience
- Professor of Oncology
- MD, Case Western Reserve University School of Medicine (1984)
- University of Michigan Health System / Neurology (1988)
- American Board of Psychiatry and Neurology / Neurology-General (1990)
Research & Publications
Selected PublicationsView all on Pubmed
Abounader R, Ranganathan S, Lal B, Fielding K, Book A, Dietz H, Burger P and Laterra J: Reversion of human glioblastoma malignancy by U1snRNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met gene expression. J Natl Cancer Inst, 91:1548-1556, 1999. PMID: 10491431.
Kim KJ, Wang L, Su, YC, Gillespie GY, Salhotra A, Lal B and Laterra J. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res, 12(4):1292-1298, 2006. PMID: 16489086
Zhou J, Tryggestad E, Wen Z, Lal B, Zhou T, Grossman R, Yan K, Wang S, Fu D-X, Blakeley J, Ford E, Tyler B, Laterra J, and van Zijl PCM: Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nature Med.2011 Jan; 17(1): 130-4. Epub Dec 19 2010. PMID: 21170048, PMCID: PMC3058561.
Li Y, Li A, Glas M, Lal B, Ying M, Sang Y, Xia S, Trageser D, Guerrero-Cázares H, Eberhart CG, Quiñones-Hinojosa A, Scheffler B, Laterra J: c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci U S A. 108:9951-6, 2011. PMID: 21628563; PMCID: PMC3116406.
Lopez-Bertoni H, Lal B, Michelson H, Guerrero-Cázares H, Quiñones-Hinojosa A, Li Y, Laterra J. Epigenetic modulation of a miR-296-5p:HMGA1 axis regulates Sox2 expression and glioblastoma stem cells. Oncogene, 2016 Feb 22. doi: 10.1038/onc.2016.22. [Epub ahead of print].
Activities & Honors
- Alpha Omega Alpha
- Journal of Neuro-Oncology
- Scientific Advisory Board of the American Brain Tumor Association
- The Society of Neuro-Oncology